PhoreMost Ltd, a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the appointment of Dr Adam Gilbert to its Scientific Advisory Board. In the role, Adam will support PhoreMost to advance its portfolio of novel small molecule degraders and molecular glues arising from its GlueSEEKER® platform. Most recently an Executive Director and External Accelerator Lead at Pfizer, Adam brings over 30 years of experience in biopharma, drug discovery, and business development. In his numerous roles at Pfizer, Adam led the Design and Synthesis Sciences platform medicinal chemistry group to successfully deliver targeted covalent inhibitors, protein homeostasis modulators, and vaccine antigens. He is co-inventor of Litfulo™ (Ritlecitinib), a covalent JAK3/TEC inhibitor that was recently approved to treat Alopecia Areata, and his group helped deliver Abrysvo™ (RSVPreF), a preventative Respiratory Syncytial Virus vaccine and Comirnaty® (BNT162b2) the Pfizer-BioNTech mRNA COVID-19 vaccine. Adam holds a PhD in organic chemistry from Columbia University.
